医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Youngevity International (YGYI) Continues International Expansion to Malaysia

2014年06月09日 PM09:05
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announced today it has taken another major step in its international expansion by opening an office in Johor Bahru, Malaysia to serve the direct selling markets in Southeast Asia.

“We are very excited about being registered in Malaysia and opening an office as we intend to increase our direct selling coverage and distribution model in the fast-growing Southeast Asian markets,” said Steve Wallach, Youngevity’s Chief Executive Officer. “Youngevity has embarked on a strategic global expansion strategy to capitalize on the growing international demand for our products and business opportunity. We are committed to investing in scalable markets with long-term growth opportunities to generate higher levels of global market penetration.”

YGY International (Malaysia) had a successful soft launch in Johor Bahru, Malaysia at the 54th National Malaysian Medical Association AGM & Scientific Meeting of the Private Medical Practitioners, a three day conference that was attended by over seven hundred medical practitioners from Malaysia and Singapore. In addition, YGY International was invited to present at the conference and provide further insight on how medicine could be better integrated with the nutritional and nutraceutical practices.

“It was an honor to be invited to speak to the top medical professionals and physicians in Malaysia. Due to the extensive research we have done with Clemson University and the University of Manitoba along with our powerful and complementary view on our products and medicine, the Association was very appreciative and we were well received,” said Sanjeev Javia, Youngevity Scientific Advisory Board Member and speaker at the conference.

About Youngevity International, Inc.

Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com) is a fast-growing, innovative, multi-dimensional company that offers a wide range of consumer products and services, primarily through person-to-person selling relationships that comprise a “network of networks.” The Company also is a vertically-integrated producer of the finest coffees for the commercial, retail and direct sales channels. The Company was formed after the merger of Youngevity Essential Life Sciences (www.youngevity.com) and Javalution Coffee Company in the summer of 2011. The company was formerly known as AL International, Inc. and changed its name to Youngevity International, Inc. in July 2013.

Safe Harbor Statement

This release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. The forward-looking statements contained in this press release include statements regarding the Company’s expected future growth, our anticipated international expansion, and the global demand for our products. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict including our ability to penetrate further the international markets and increase the demand for our products. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

CONTACT

Youngevity International, Inc.
Investor Relations
John
Zervas

800-982-3189 X 6509

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent